Thimiri Govindaraj, Deepak BNxumalo, Precious Z2022-04-042022-04-042021-02Thimiri Govindaraj, D.B. & Nxumalo, P.Z. 2021. CSIR technology platform for cancer precision medicine. http://hdl.handle.net/10204/12367 .http://hdl.handle.net/10204/12367Dr. Deepak Balaji Thimiri Govindaraj has been selected for an e-Poster presentation at the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukaemia. The Conference is proposing a programme of leading-edge basic and clinical science where a panel of global experts in the field will provide numerous opportunities for formal and informal interactions to discuss the present and the future of CLL research. It is open to an international audience of biologists and clinicians, particularly welcoming those in-training. This translational research conference will explore the most recent advances in the understanding of the pathogenesis and clinical management of the disease. Open and spirited discussion on the most up-to-date information in the field is expected to understand how the many new biologic insights apply to the future of CLL. The main issue with current Ovarian Cancer (OvCa), Chronic lymphocytic leukemia (CLL) and Multiple Myeloma (MM) treatment is the eventual resistance to standard chemotherapy which ultimately leads to patient relapse. Overcoming platinum resistance  is an unmet medical need in OvCa, CLL, MM patients  which we plan to address with our technology pipeline. We propose a game changing, disruptive technology pipeline with which we will identify drugs and drug combinations for relapsed CLL, MM and OvCa patients who exhausted all other treatment options. Our technology pipeline includes strategies where we combine new microfluidic-based technology with our established high-throughput drug screening platform. Using our pipeline, we aim to identify drug combinations that can overcome platinum resistance and ultimately provide tailored-specific therapy options for CLL, MM and OvCa patients . Approach: The aim of the proposal is to establish robust drug screening platform which can identify drugs and drug combinations that are effective in precision medicine for individual CLL, MM and OvCa patients. We propose a strategy where we use combination of our newly established platform for drug screening with patient samples, flow cytometry-based signaling analysis, and microfluidics based single cell drug screening methodology towards precision medicine for ovarian cancer patients. FulltextenCancer precision medicineChronic Lymphocytic LeukaemiaCLLMultiple MyelomaOvarian cancerConference PresentationThimiri Govindaraj, D. B., & Nxumalo, P. Z. (2021). CSIR technology platform for cancer precision medicine. http://hdl.handle.net/10204/12367Thimiri Govindaraj, Deepak B, and Precious Z Nxumalo. "CSIR technology platform for cancer precision medicine." <i>CSIR technology platform for cancer precision medicine</i> (2021): http://hdl.handle.net/10204/12367Thimiri Govindaraj DB, Nxumalo PZ, CSIR technology platform for cancer precision medicine; 2021. http://hdl.handle.net/10204/12367 .TY - Conference Presentation AU - Thimiri Govindaraj, Deepak B AU - Nxumalo, Precious Z AB - Dr. Deepak Balaji Thimiri Govindaraj has been selected for an e-Poster presentation at the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukaemia. The Conference is proposing a programme of leading-edge basic and clinical science where a panel of global experts in the field will provide numerous opportunities for formal and informal interactions to discuss the present and the future of CLL research. It is open to an international audience of biologists and clinicians, particularly welcoming those in-training. This translational research conference will explore the most recent advances in the understanding of the pathogenesis and clinical management of the disease. Open and spirited discussion on the most up-to-date information in the field is expected to understand how the many new biologic insights apply to the future of CLL. The main issue with current Ovarian Cancer (OvCa), Chronic lymphocytic leukemia (CLL) and Multiple Myeloma (MM) treatment is the eventual resistance to standard chemotherapy which ultimately leads to patient relapse. Overcoming platinum resistance  is an unmet medical need in OvCa, CLL, MM patients  which we plan to address with our technology pipeline. We propose a game changing, disruptive technology pipeline with which we will identify drugs and drug combinations for relapsed CLL, MM and OvCa patients who exhausted all other treatment options. Our technology pipeline includes strategies where we combine new microfluidic-based technology with our established high-throughput drug screening platform. Using our pipeline, we aim to identify drug combinations that can overcome platinum resistance and ultimately provide tailored-specific therapy options for CLL, MM and OvCa patients . Approach: The aim of the proposal is to establish robust drug screening platform which can identify drugs and drug combinations that are effective in precision medicine for individual CLL, MM and OvCa patients. We propose a strategy where we use combination of our newly established platform for drug screening with patient samples, flow cytometry-based signaling analysis, and microfluidics based single cell drug screening methodology towards precision medicine for ovarian cancer patients.  DA - 2021-02 DB - ResearchSpace DP - CSIR J1 - CSIR technology platform for cancer precision medicine KW - Cancer precision medicine KW - Chronic Lymphocytic Leukaemia KW - CLL KW - Multiple Myeloma KW - Ovarian cancer LK - https://researchspace.csir.co.za PY - 2021 T1 - CSIR technology platform for cancer precision medicine TI - CSIR technology platform for cancer precision medicine UR - http://hdl.handle.net/10204/12367 ER -25511